Erafos 3gm Granules contain Fosfomycin 3gm, a broad-spectrum antibiotic used primarily for the treatment of uncomplicated urinary tract infections (UTIs) caused by susceptible strains of bacteria. Fosfomycin acts by inhibiting bacterial cell wall synthesis, leading to bactericidal activity against a wide range of gram-positive and gram-negative pathogens, including Escherichia coli and Enterococcus faecalis. The granules are intended for oral administration and are typically reconstituted in water before use, providing a convenient single-dose regimen that enhances patient compliance. Erafos is particularly effective in treating acute cystitis in women, offering rapid symptom relief and eradication of infection. It is generally well tolerated, with a low incidence of adverse effects such as gastrointestinal disturbances, including diarrhea, nausea, and abdominal pain. Fosfomycin exhibits minimal systemic absorption, reducing the risk of systemic toxicity and drug interactions. Caution is advised in patients with known hypersensitivity to fosfomycin or related compounds. Erafos should be used in accordance with susceptibility data and clinical guidelines to prevent the development of resistance. It is contraindicated in severe renal impairment and should be prescribed under medical supervision to ensure appropriate use and monitoring.